^
abcCohen JD, Van Putten T, Marder S, Berger PA, Stahl SM (October 1987). "The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia". Journal of Clinical Psychopharmacology. 7 (5): 324–9.
doi:
10.1097/00004714-198710000-00006.
PMID2890671.
^Olson GL, Cheung HC, Morgan KD, et al. (September 1981). "A dopamine receptor model and its application in the design of a new class of rigid pyrrolo[2,3-g]isoquinoline antipsychotics". Journal of Medicinal Chemistry. 24 (9): 1026–34.
doi:
10.1021/jm00141a002.
PMID6116805.
^
abDavidson AB, Boff E, MacNeil DA, Wenger J, Cook L (1983). "Pharmacological effects of Ro 22-1319: a new antipsychotic agent". Psychopharmacology. 79 (1): 32–9.
doi:
10.1007/BF00433013.
PMID6132425.
S2CID12070196.
^Pugh MT, O'Boyle KM, Molloy AG, Waddington JL (1985). "Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213". Psychopharmacology. 87 (3): 308–12.
doi:
10.1007/BF00432713.
PMID2934758.
S2CID19324697.
^Molloy AG, O'Boyle KM, Pugh MT, Waddington JL (July 1986). "Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists". Pharmacology Biochemistry and Behavior. 25 (1): 249–53.
doi:
10.1016/0091-3057(86)90262-5.
PMID3529126.
S2CID7007444.
^Collin S, Vercauteren DP, Vanderveken D, Evrard G, Durant F (March 1989). "Structural requirements of Na+-dependent antidopaminergic agents: Tropapride, Piquindone, Zetidoline, and Metoclopramide. Comparison with Na+-independent ligands". Journal of Computer-aided Molecular Design. 3 (1): 39–53.
Bibcode:
1989JCAMD...3...39C.
doi:
10.1007/BF01590994.
PMID2715795.
S2CID13298150.
^Uhr SB, Berger PA, Pruitt B, Stahl SM (October 1984). "Treatment of Tourette's syndrome with RO22-1319, a D-2-receptor antagonist". The New England Journal of Medicine. 311 (15): 989.
doi:
10.1056/NEJM198410113111517.
PMID6147753.
^Uhr SB, Pruitt B, Berger PA, Stahl SM (April 1986). "Case report of four patients with Tourette syndrome treated with piquindone, a D2 receptor antagonist". Journal of Clinical Psychopharmacology. 6 (2): 128–30.
doi:
10.1097/00004714-198604000-00028.
PMID2871057.
^Uhr SB, Pruitt B, Berger PA, Stahl SM (July 1986). "Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist". International Clinical Psychopharmacology. 1 (3): 216–20.
doi:
10.1097/00004850-198607000-00004.
PMID3549873.